ProPhase Labs, Inc. (NASDAQ:PRPH) Sees Large Increase in Short Interest

ProPhase Labs, Inc. (NASDAQ:PRPH) saw a significant increase in short interest in February. As of February 15th, there was short interest totalling 4,420,000 shares, an increase of 5,106.1% from the January 31st total of 84,900 shares. Based on an average trading volume of 8,590,000 shares, the short-interest ratio is currently 0.5 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. SVB Wealth LLC purchased a new stake in shares of ProPhase Labs in the 4th quarter valued at $36,000. Squarepoint Ops LLC purchased a new position in shares of ProPhase Labs in the fourth quarter worth about $40,000. Warberg Asset Management LLC bought a new stake in shares of ProPhase Labs in the 4th quarter valued at about $77,000. Perritt Capital Management Inc grew its holdings in shares of ProPhase Labs by 129.1% in the fourth quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock worth $144,000 after purchasing an additional 107,068 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of ProPhase Labs by 26.6% in the fourth quarter. Geode Capital Management LLC now owns 203,528 shares of the company’s stock valued at $154,000 after acquiring an additional 42,793 shares during the period. 9.45% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on shares of ProPhase Labs in a report on Tuesday. They issued a “sell” rating on the stock.

ProPhase Labs Price Performance

Shares of PRPH stock traded up $0.08 during trading on Thursday, hitting $0.52. The company had a trading volume of 4,207,533 shares, compared to its average volume of 14,637,283. ProPhase Labs has a 52 week low of $0.22 and a 52 week high of $7.48. The stock has a market capitalization of $12.39 million, a price-to-earnings ratio of -0.40 and a beta of -0.37. The company has a quick ratio of 1.33, a current ratio of 1.47 and a debt-to-equity ratio of 0.48. The stock’s 50-day moving average is $0.52 and its two-hundred day moving average is $1.42.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.